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The importance of murine monokines and lymphokines in T  cell immune responses 
has  been emphasized  by the  development  of T  cell  cloning technology (1)  and  the 
identification of cloned tumor lines that respond to or secrete these factors (2, 3). Such 
studies have shown that the monokine interleukin  1 (IL-1) 1 induces certain T  cells to 
secrete  interleukin  2  (IL-2),  and  that  this  lymphokine can  maintain  continuous  in 
vitro proliferation  of some T  cell  subsets.  In contrast,  the  interaction  of monokines 
and lymphokines with B cells is poorly understood, partly because of the lack of assays 
for  B  cell  function  in  which  contaminating  accessory  cells  capable  of mediating 
secondary effects have been excluded. We have recently described a procedure for the 
long-term  culture  of normal  mouse  B  lymphocytes in  which  induced  supernatants 
from a T  cell hybridoma sustain slow proliferation of lipopolysaccharide-activated  B 
cells for periods of up to 12 mo (4).  This procedure implied the existence of a T  cell- 
derived  growth  factor  that  interacts  with  activated  B  lymphocytes  to  maintain 
proliferation. Here we identify such a  factor in induced supernatants  from the mouse 
thymoma EL4. This material is distinct from previously recognized factors, including 
IL-2. 
Materials  and Methods 
Mice.  BALB/c mice were obtained from The Jackson Laboratory, Bar Harbor, ME and 
used at 8-12 wk of age. 
Anti-lgM Antibody.  Affinity column-purified goat anti-mouse immunoglobulin (Ig) specific 
for # heavy chains (anti-#)  was prepared as previously described (5). 
Factor Preparations.  EL4 supernatant was prepared by stimulating a cloned subline of EL4 
thymoma with 10 ng/ml phorbol myristate acetate (PMA) as described elsewhere (2). Cell-free 
supernatants  were  collected  after  48  h  and  depleted  of PMA by absorption  on  activated 
charcoal (6). B151KI2 supernatant was collected from the cloned T cell hybridoma B151K12 
produced by Takatsu and colleagues (7). 
B  Cell Purification.  Small splenic B cells were enriched as described by Leibson et al.  (8). 
BALB/c mice were treated  with 0.04  mi anti-thymocyte serum  (Microbiological Associates, 
* Supported by a C. J. Martin Fellowship from the National Health and Medical Research Council of 
Australia. 
1 Abbreviations  used  in this  paper: AFC, antibody-forming cells; BCGF, B cell growth factor; IL- 1, interleukin 
1; IL-2, interleukin 2; PFC, plaque-forming cells; PMA, phorbol myristate acetate; SDS-PAGE, sodium 
dodecyl sulfate-polyacrylamide  gel eleetrophoresis; SRC, sheep erythrocytes; TRF, T cell-replacing factor. 
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Walkersville, MD), and spleen cells harvested 2 d later were depleted of maerophages, activated 
lymphocytes, and other adherent cells by passage over Sephadex G10 as described by Ly and 
Mishell (9). T cells and null cells were subsequently removed by two treatments with a battery 
of cytotoxic antibodies  (4°C, 45 min), followed by guinea pig complement at a  1:4 dilution 
(37°C, 45 rain).  The antibodies comprised a monoelonal mouse anti-Thy-l.2 antibody (New 
England Nuclear, Boston, MA), a noncytotoxic monoelonal rat anti Lyt-1 antibody (generously 
provided by J.  Ledbetter,  Stanford University, Paolo Alto, CA) combined with  a  cytotoxie 
monoclonal mouse anti-rat x antibody (MAR 18.5, generously provided by L. Lanier, University 
of New Mexico, Albuquerque, NM), and a monoclonal mouse cell antibody specific for certain 
splenic  null  cells  (MK 2.2,  generously provided by P.  Marrack,  National Jewish  Hospital, 
Denver,  CO).  The  cells  obtained  by  this  method  comprised  20-30%  of the  initial  B  cell 
population, were all small lymphocytes by density gradient analysis, were 98-99% Ig-positive 
by immunofluorescence,  and  showed  the normal  range  of B  ci~ll immunocompetence in  a 
variety of filler-supplemented assay systems (unpublished data). 
B Cell Co-Stimulator Assay.  Purified B cells were cultured at densities ranging from 5 ×  104 
to 5  ×  105 cells/well  in 200 #1 of medium in flat-bottomed 96-well  microtiter plates  (3596; 
Costar,  Data  Packaging,  Cambridge,  MA).  The  culture  medium  was  RPMI  1640  (Gibeo 
Laboratories, Grand Island, NY) supplemented with  10% fetal calf serum (Reheis,  Kankakee, 
IL), penicillin (50 #g/ml), streptomycin (50/~g/ml), gentamicin (100/~g/ml), L-glutamine (200 
mM), and 2-mereaptoethanol (5 ×  10  -5 M). Some cultures contained goat anti-# antibody (1- 
50/~g/ml) and/or dilutions of the various factor preparations. Cultures were incubated at 37°C 
in a humidified atmosphere of air containifi~ 7.5% CO2 for 3 d. The proliferative response of 
these  cultures  was  determined  by adding  [ H]thymidine  for the  last  16  h  of culture  and 
measuring [3H]thymidine incorporation as previously described (5). 
Absorption oflL-2.  IL-2-containing supernatants were depleted of IL-2 by absorbing them 
twice with the IL-2-dependent cytotoxic T cell clone CT6, each time incubating 107 CT6 cells 
with  1 ml ofsupernatant for 2 h at 37°C (10). 
Gel Filtration Analysis.  PMA-induced EL4 supernatants  were fractionated on a  calibrated 
AcA54 column exactly as described previously (2). 
IL-2 Assay.  IL-2 activity was measured by culturing CT6 cells at  104 cells/well for 24 h in 
medium containing various dilutions of the test supernatant. Proliferation was quantitated by 
the addition of [3H]thymidine during the final 5 h. 
B Cell Growth Factor Assay.  The standard B cell growth factor assay developed in this study 
involved  the  co-culture  of 5  ×  104  purified  B  cells/well,  anti-IgM  antibodies  at  a  final 
concentration  of 5 #g/ml,  and  varying dilutions  of PMA-induced  EL4 supernatant  either 
before or  after  fractionation.  Cultures  were  incubated  for 3  d,  with  a  final  16-h  pulse  of 
[SH]thymidine. 
For both IL-2 and B cell growth factor assays, a relative unit of activity was defined as the 
amount of material required to produce 50% of the proliferation caused by a saturating amount 
of EL4 supernatant. Thus, the inverse of the dilution that produced 50% of the proliferation 
obtained with a saturating level of EL4 supernatant  defined the number of relative units per 
milliliter. 
Enumeration of Antibody-forming Cells (AFC).  5  ×  105  purified  B  cells  were  cultured  in 
microtiter wells,  together with  10/~1 of 0.1% erythrocytes (SRC)  per well  and various factor 
preparations.  SRC-specific direct  hemolytic plaque-forming cells  (PFC)  were measured  4  d 
later. 
Results 
T  Cell-mediated Enhancement ofAnti-lg-induced B  Cell Proliferation.  A short-term B cell 
co-stimulator assay was developed to identify stimuli required for B cell proliferation. 
This assay, based on Parker's  (11)  demonstration of a  T  cell supernatant  enhancing 
the proliferation of anti-IgM stimulated B cells, involved the short-term co-culture of 
highly  purified  resting  B  lymphocytes  with  anti-IgM,  together  with  supernatant 
obtained  from stimulated  EL4 cells.  When 5  ×  105 purified B cells were cultured  in 
200 ~1 of culture medium containing affinity-purified goat anti-IgM antibodies  at a 916  HOWARD  ET AL. 
final concentration of 50/~g/ml,  a  good proliferative response was obtained  (Fig.  1), 
as has been reported from this (5) and other (12) laboratories. However, this response 
rapidly  deteriorated to near background levels when the anti-IgM  concentration or 
the B  cell density was decreased to  10/~g/ml  or 5  ×  104 cells/well,  respectively  (Fig. 
1).  To ascertain whether T  cell-derived  helper factors were limiting  in these experi- 
ments,  they  were  repeated,  this  time  with  the  addition  of a  supernatant  obtained 
from a subline of EL4 thymoma after stimulation with PMA. Such supernatants have 
been shown to be potent sources of T  cell-derived lymphokines (2,  10). As little as 5% 
EL4  supernatant  was found  to produce two striking effects:  (a)  a  shift  in antibody 
dose/response, such  that  5 #g/ml  anti-IgM  plus  EL4  supernatant  induced  levels of 
= 60t70  5x 105 B CELLS/WELL  t105 B  CELLS/WELL  ///~  _-Sx  104 B CELLS/WELL 
~4~  + EL4Supt. 
[anti-lgM  I ~g / ml 
F]o.  1.  Proliferative response of purified B  cells  to  anti-IgM,  cultured in  the  presence  (0)  or 
absence (O) of EL4 supernatant added at a final concentration of 5%.  All groups were cultured in 
triplicate and incubated for 3 d with the addition of [3H]thymidine for the last 16 h. 
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proliferation greater than those induced by 50/~g/ml anti-IgM alone (Fig.  1); and (b) 
a  shift in cell density/response such that a  significant  response to 5-50 #g/ml anti- 
IgM could be obtained with as few as 5 X  104 B cells/well (Fig. 1). We show elsewhere 
that 5% EL4 supernatant  is in fact saturating in these experiments (M.  Howard, B. 
Johnson, and W. E. Paul, manuscript submitted). In all subsequent experiments, the 
combination of 5 ×  104 B cells/well and 5/~g/ml anti-IgM was chosen as the routine 
condition  for assaying the T  cell-derived B cell co-stimulating factor present in EL4 
supernatants. 
Distinction between the B  Cell Co-stimulation Factor and IL-2.  As PMA-induced  EL4 
supernatants  are potent sources of IL-2 (2), it was important  to determine whether 
IL-2 caused the B cell co-stimulator activity described above, either directly or via its 
action on residual T cells. To address this possibility, a PMA-induced EL4 supernatant 
was depleted of IL-2 by extensive absorption on the cloned IL-2-dependent T  cell line 
CT6. The absorbed supernatant and an aliquot of the original unabsorbed superna- 
tant were assayed for both B cell co-stimulator activity, and for IL-2 activity using 
proliferation of CT6 cells as an assay. Absorption reduced IL-2 content from 40 U/ml 
to <0.1  U/ml, but caused little or no reduction  in B cell co-stimulator activity (Fig. 
2). Further evidence that IL-2 and the B cell co-stimulating factor are distinct entities 
was provided by gel filtration charaGterization of the factors. A crude PMA-induced 
EL4 supernatant  was concentrated  and then  fractionated on an AcA54  column  as 
described  previously  (2).  Each  fraction was dialyzed  against culture  medium, then 
tested for IL-2 and B cell co-stimulator activity at several serial dilutions.  As shown 
in  Fig.  3,  the  major peaks of IL-2 and  B  cell  co-stimulator  activities were clearly 
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Fie.  3.  Gel filtration analysis of IL-2 and BCGF activities in EL4 supernatant. Fractions collected 
from an  AcA54  column were dialyzed  and  then  assayed  for BCGF  and  IL-2 activity.  Units of 
activity  were calculated  as  described  in  text.  The  calibrating  molecular  weight  markers  were: 
ovalbumin (43,500),  myoglobin (18,800),  and cytochrome c (12,384).  O, units of BCGF per ml; O, 
units of IL-2 per ml. 918  HOWARD  ET  AL. 
separable by this procedure, with their approximate molecular weights being 30,000- 
35,000  and  16,500-18,500,  respectively. The  16,500-18,500  Mr  material  produced 
little or no proliferation in control B cell cultures from which anti-IgM antibodies 
had been omitted. This result was repeated in two further experiments using AcA54 
fractions prepared  from separate  PMA-induced EL4 supernatants.  The  molecular 
weight estimate for IL-2 obtained in these experiments agrees with that reported by 
us (13) and by three other laboratories on the basis of gel filtration analysis (14-16). 
We have recently confirmed the molecular weight estimate for B cell co-stimulator 
activity by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) 
analysis  (J.  Farrar,  M.  Howard, J.  Fuller-Farrar,  and  W.  E.  Paul,  manuscript  in 
preparation).  For  convenience,  the  18,000  Mr  B  cell  co-stimulator  from  the  EL4 
thymoma was termed B cell growth factor (BCGF). 
Although the major peaks of IL-2 and BCGF activities were clearly distinct by gel 
filtration analysis, a  variable amount of contaminating IL-2 activity was sometimes 
found in the 18,000 Mr region of AcA54-fractionated EL4 supernatants (e.g., see Fig. 
3). To eliminate the possibility that the BCGF activity observed in our experiments 
reflected a primary or secondary IL-2-mediated effect, or alternatively, the result of 
a  synergistic interaction between IL-2 and BCGF, a  pool was made of the AcA54 
fractions constituting the major peak of BCGF activity (see hatched area of Fig. 3), 
and this material was absorbed  extensively on CT6 cells.  The absorbed  18,000  Mr 
material was greatly depleted of the residual IL-2 activity, while showing no significant 
reduction in BCGF activity (Fig. 4). A procedure for absorbing contaminating BCGF 
but not IL-2 from the 30-35,000 Mr material obtained from AcA54 columns is not yet 
available. However, we show elsewhere that a more complete separation of IL-2 and 
BCGF can be achieved using a  phenyl sepharose column to fractionate EL4 super- 
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FIG.  4.  BCGF and IL-2 activity in an unfractionated EL4 supernatant and in an 18,000 Mr cut of 
the same supernatant before and after absorption on cloned CT6 T  cells. The 18,000 M, material 
was prepared by gel filtration and corresponds to the hatched area shown in Fig. 3. B  CELL GROWTH  FACTOR DISTINCT FROM  INTERLEUKIN 2  919 
TABLE  I 
Nonspecific Factor Requirements  for an SRC-specific AFC Response 
Group 
Factor additions to the B cell 
cultures* 
Anti-SRC AFC per 
10  n B cells¶ 
IL-2:]:  BCGF§  TRFII  Experi-  Experi- 
ment 1  ment 2 
A  --  --  --  0  0 
B  1:200  --  --  2  0 
C  --  1:200  --  0  0 
D  --  1:4  0  0 
E  1:200  1:200  --  2  0 
F  1:200  --  1:4  8  2 
G  1:200  1:4  8  10 
H  1:200  1:200  1:4  76  93 
I  1:20  --  --  0  ND** 
J  --  1:20  --  0  ND 
K  --  --  1:4  0  ND 
L  1:20  1:20  --  0  ND 
M  1:20  --  1:4  7  ND 
N  --  1:20  1:4  0  ND 
O  1:20  1:20  1:4  120  ND 
* Factors were added at the dilutions indicated simultaneously with SRC on 
day 0 to cultures containing 5 ×  105 B cells. 
:~ A pool of active fractions from a preparative isoelectric focusing experiment. 
Preparation free of BCGF. 
§ A pool of active fractions from a preparative isoeleetric focusing experiment. 
Preparation free of IL-2. 
[I Unfractionated B 151K 12 hybridoma supernatant.  Preparation free of IL-2 
and BCGF. 
¶ Antibody-forming cells measured on day 4. All groups comprised triplicate 
cultures. 
** Not determined. 
natants  (10).  The  BCGF-free  IL-2-containing  material  obtained  by  this  procedure 
totally  lacks  the  ability  to  synergize  with  anti-IgM  antibodies  for  induction  of 
polyelonal B  cell proliferation  (10). 
Requirement for BCGF in an AFC Response.  To  further  explore the role of BCGF  in 
B  cell immune  responses, the stimuli required for AFC production  by highly purified 
B  cells were investigated. As expected, B  cells depleted of accessory cells, as described 
above,  failed  to  generate  SRC-specific  AFC  when  cultured  with  SRC  for 4  d  in  a 
standard  in vitro AFC  assay  (Table I, group A). To test whether  BCGF  and/or  IL-2 
could  compensate  for  the  depleted  accessory  cell  function,  it  was  desirable  to  use 
preparations  of these factors purer than those obtained from AcA54 column  fraction- 
ation.  A  full biochemical characterization  of BCGF  is presented  elsewhere  (J.  Farar, 
M. Howard, J. Fuller-Farrar, and W. E. Paul, manuscript  in preparation),  and shows 
that  more  complete  separation  of  BCGF  and  IL-2  is  possible  either  by  phenyl 
sepharose chromatography,  by SDS-PAGE,  or by isoelectric-focusing. Thus, relatively 
pure preparations  of BCGF and IL-2 were produced by isoelectric focusing ofa  PMA- 
induced  EL4  supernatant,  and  an  amount  of each  found  to  be  saturating  in  the 
appropriate  proliferation  assay was added  to cultures containing purified B  cells and 
SRC  antigen.  Both lymphokines  failed to induce antigen-activated  B  cells to develop 920  HOWARD ET  AL. 
into AFC, either individually or in combination (Table I, groups B, C, E, I, J, and L). 
It has recently been proposed  (11,  I7)  that antigen-induced AFC responses require 
two functionally distinct nonspecific T cell factors: one to enhance B cell proliferation 
and the other to provide a  differentiation signal. To provide an independent source 
of the latter, we used supernatant from the T  cell-replacing factor (TRF)-secreting 
hybridoma BI51K12 produced by Takatsu and colleagues (7). This supernatant was 
found to lack both BCGF and IL-2 activity (K. Nakanishi and M. Howard, unpub- 
lished data) and was insufficient by itself or in combination with either BCGF or IL- 
2 to support the production of specific AFC in cultures of purified B cells and SRC 
antigen (Table I, groups D, F, G, K, M, and N). However, an excellent SRC-specific 
AFC response was obtained in B cell cultures containing a  combination of antigen, 
BCGF, IL-2, and B151K12 supernatant as a source of TRF (Table I, groups H  and 
O). These responses were antigen specific both in terms of requiring the presence of 
antigen and of not including generation of AFC with unrelated specificities (unpub- 
lished data).  From these data, we conclude that the B cell proliferation-enhancing 
factor BCGF is required for the production of SRC-specific AFC. In view of the high 
number of purified B cells required for the experiments summarized in Table I, the 
chance  for residual  T  cell and  macrophage contamination is markedly increased. 
Thus, it should not be assumed that the other factors required for AFC production 
(i.e., IL-2 and B151K12 supernatant) are acting directly on B cells. 
Discussion 
We describe in this report a factor, BCGF, that synergizes with anti-IgM antibodies 
to cause po!yclonal B cell proliferation. The small number of highly purified target B 
cells and the absolute requirement for anti-IgM in the proliferation experiments make 
it highly unlikely that BCGF is acting on a contaminating non-B cell present in the 
cultures. The action of BCGF is seemingly restricted to DNA synthesis and does not 
include AFC production unless additional factors are provided. When these additional 
factors are  provided, BCGF is  found to be an essential component of an antigen- 
specific AFC  response.  The  evidence  presented  qualifies  BCGF  as  a  new  T  cell 
lymphokine. It can be distinguished both functionally and by molecular weight from 
other previously described T  cell factors, namely IL-2 (1,  13-16), TRF (18), colony- 
stimulating factor  (19),  interleukin  3  (20),  and  B  cell  replication  and  maturation 
factor  (21).  BCGF  does  not  induce  proliferation  of phytohemagglutin-stimulated 
thymocytes (unpublished data) and so is distinct from the monokine IL-1 (22). The 
biochemical properties of this molecule are presented in greater detail elsewhere (J. 
Farrar, M.  Howard, J.  Fuller-Farrar, and W.  E.  Paul, manuscript in preparation) 
and  further support  its novelty. The  proportion  of B  cells responsive  to  BCGF is 
unclear.  The  levels  of proliferation  obtained  in  these  studies  are  consistent  with 
involvement of the entire anti-IgM-activated B cell pool, a pool recently quantitated 
to  be  -50%  of normal  B  cells  (23).  BCGF-Iike activity can  be  found in  antigen- 
induced supernatants from normal T cell helper lines propagated in long-term culture 
as described by Kimoto and Fathman (24)  (K. Nakanishi and M. Howard, unpub- 
lished  data).  We  are  currently  investigating  the  phenotype  of normal  cells  that 
produce BCGF. 
An  additional point  of interest to emerge from this study is  the  role  for the Ig 
receptor in B cell activation. Although the sequence in which anti-IgM and BCGF B CELL GROWTH  FACTOR DISTINCT FROM  INTERLEUKIN  2  921 
signal the B cell cannot be implied from the above experiments, we have found that 
proliferation can be extended beyond the  3-d co-stimulator assay by the continued 
addition  of BCGF but not anti-IgM (unpublished observations). In light of this, we 
propose the following model of B cell activation: that BCGF has no action on resting 
B  cells;  that  anti-Ig delivers  a  nonproliferative  signal  to  resting  B  cells,  possibly 
causing the expression of receptors for BCGF; and that BCGF delivers a proliferation 
signal  to  these  anti-Ig-activated,  growth  factor-sensitive B  cells.  Thus,  the  overall 
concept is analogous to currently proposed models for T  cell activation (25-27).  We 
wish to emphasize this model pertains only to the 50% of B cells that can be activated- 
by anti-IgM  (23)  and  thus  does not  exclude the existence of a  separate subset of B 
cells  that  interact  with  T  cells  in  an  H-2-restricted  manner.  Such  a  division  of B 
lymphocytes is in fact consistent with the recent work of Singer et al. (28). Similarly, 
we  cannot  exclude  the  possibility  that  other  lymphokines  or  monokines  may  be 
involved in enhancing, modifying, or regulating this entire process. 
Summary 
We report here a factor (B cell growth factor) found in induced supernatants of the 
mouse  thymoma  EL4  that  co-stimulates  with  anti-IgM  antibodies  in  short-term 
cultures of purified B lymphocytes to induce polyclonal B cell proliferation but not 
antibody-forming cell production.  The factor is not mitogenic for resting B cells and 
interacts with anti-IgM-activated B cells in a non-H-2-restricted manner. Absorption 
studies and molecular weight analysis reveal the factor is distinct from interleukin 2. 
This  factor synergises with  antigen,  interleukin  2,  and  an  interleukin  2-free, B  cell 
growth factor-free T  cell supernatant that contains T  cell-replacing factor to produce 
erythrocyte-specific plaque-forming cells in cultures of highly purified B cells. 
We thank A. DeFranco and R. Asofsky for providing affinity-purified goat anti-mouse IgM 
antibodies, and J. Fuller-Farrar for assistance with gel filtration analyses. 
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